Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms

NCT05074355 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Myeloproliferative Neoplasm

Interventions

DRUG: Azacitidine
DRUG: Venetoclax

Sponsor

University Health Network, Toronto